Literature DB >> 34074315

Correction to: Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study.

Eugen Mengel1, Bruno Bembi2, Mireia Del Toro3, Federica Deodato4, Matthias Gautschi5, Stephanie Grunewald6, Sabine Grønborg7, Bénédicte Héron8, Esther M Maier9, Agathe Roubertie10, Saikat Santra11, Anna Tylki-Szymanska12, Simon Day13, Tara Symonds14, Stacie Hudgens15, Marc C Patterson16, Christina Guldberg17, Linda Ingemann17, Nikolaj H T Petersen17, Thomas Kirkegaard17, Christine Í Dali17.   

Abstract

Entities:  

Year:  2021        PMID: 34074315      PMCID: PMC8168003          DOI: 10.1186/s13023-021-01855-9

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


× No keyword cloud information.

Correction to: Orphanet Journal of Rare Diseases (2020) 15:328 https://doi.org/10.1186/s13023-020-01616-0

Following the publication of the original article [1], it was brought to the authors’ attention that there are several errors within the article, introduced through both typographical and editorial oversight as well as through final typesetting. The errors and their respective corrections are shown in Table 1. The authors apologise for these errors, but note that the results and conclusions of the manuscript remain unchanged.
Table 1

.

ErrorCorrection

Abstract background, page 1:

cholestane-3β,5α-,6β-triol

cholestane-3β,5α,6β-triol

Abstract results, page 1, lines 4-7:

Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p < 0.0001), HSP70 (p < 0.0001) and skin unesterified cholesterol (p = 0.0006). Cholestane-triol levels were significantly higher in individuals with NPC versus healthy individuals (p = 0.008) and correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411).

Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p < 0.0001) and HSP70 (p < 0.0001), and significantly higher levels of skin unesterified cholesterol (p = 0.0006). Cholestane-triol levels were also significantly higher in individuals with NPC versus healthy individuals (p = 0.008) and were correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411).

Abstract trial registration, page 2:

2014–005,194-37

2014-005193-37

Background, page 2, paragraph 2, line 9:

that affect gross motor skills, swallowing ability cogni-

that affect gross motor skills, swallowing ability and cogni-

Results, page 4, paragraph 4, line 11:

tion still had an end-of-trial visit and provided data for

tion still had an end of study visit and provided data for

Results, page 4, paragraph 6, line 3:

by referring clinicians as current medical conditions, was

by referring clinicians as current medical conditions, were

Results, page 4, paragraph 7, line 9:

(Fig. 3b).

(Fig. 3c).

Figure 3 legend, line 4,

an end-of-trial visit and is included in efficacy assessments

an end of study visit and is included in efficacy assessments

Table 3, row 1:

Total number of different alleles

Total number of distinct alleles

Table 4, title:

Change in disease biomarkers over the 6–14-month observation period compared with those of healthy individuals

Disease biomarkers over the 6–14-month observation period and those of healthy individuals

Results, page 8, paragraph 4, line 20:

(Table 6).

(Table 7).

Figure 5 legend, line 1-2:

a. PBMC unesterified cholesterol. b. Skin unesterified cholesterol.

a. Skin unesterified cholesterol. b. PBMC unesterified cholesterol.

Table 5, line 20:

Serious adverse events [indented]

This is incorrectly indented, please align to the left.
Table 6Table 7
Table 7Table 6

Results, page 11, paragraph 2, line 12:

(Table 7).

(Table 6.)

Table 7, heading:

MEAN 5-domain NPCCSS score (±SD)

Mean 5-domain NPCCSS score (±SD)

Discussion, page 12, paragraph 1, line 12-13:

date and to confirm the patients and clinicians view on

clinical meaningful changes on the 5-domain NPCCSS

date and to confirm the patients’ and clinicians’ views on

clinically meaningful changes on the 5-domain NPCCSS

Discussion, page 13, paragraph 2, line 12:

tane burden with NPC disease severity [22]. However,

tane triol burden with NPC disease severity [22]. However,

Discussion, page 13, paragraph 3, line 19:

this was likely owing to the limited viability of PBMCs

this was likely due to the limited viability of PBMCs

Discussion, page 14, paragraph 3, line 11:

uting to the 5-domain NPCCSS were locally independent

uting to the 5-domain NPCCSS was locally independent

Methods, page 15, paragraph 2, line 9:

Incorrect formatting of citation (15)

Delete

Methods, page 16, paragraph 6, line 22:

Incorrect formatting of abbreviation and citation (ICC2,13)

(ICC) [2,13]

Abbreviations:

MCID: Minimal clinically important difference;

Delete
. Abstract background, page 1: cholestane-3β,5α-,6β-triol Abstract results, page 1, lines 4-7: Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p < 0.0001), HSP70 (p < 0.0001) and skin unesterified cholesterol (p = 0.0006). Cholestane-triol levels were significantly higher in individuals with NPC versus healthy individuals (p = 0.008) and correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient = 0.265, p = 0.0411). Abstract trial registration, page 2: 2014–005,194-37 Background, page 2, paragraph 2, line 9: that affect gross motor skills, swallowing ability cogni- Results, page 4, paragraph 4, line 11: tion still had an end-of-trial visit and provided data for Results, page 4, paragraph 6, line 3: by referring clinicians as current medical conditions, was Results, page 4, paragraph 7, line 9: (Fig. 3b). Figure 3 legend, line 4, an end-of-trial visit and is included in efficacy assessments Table 3, row 1: Total number of different alleles Table 4, title: Change in disease biomarkers over the 6–14-month observation period compared with those of healthy individuals Results, page 8, paragraph 4, line 20: (Table 6). Figure 5 legend, line 1-2: a. PBMC unesterified cholesterol. b. Skin unesterified cholesterol. Table 5, line 20: Serious adverse events [indented] Results, page 11, paragraph 2, line 12: (Table 7). Table 7, heading: MEAN 5-domain NPCCSS score (±SD) Discussion, page 12, paragraph 1, line 12-13: date and to confirm the patients and clinicians view on clinical meaningful changes on the 5-domain NPCCSS date and to confirm the patients’ and clinicians’ views on clinically meaningful changes on the 5-domain NPCCSS Discussion, page 13, paragraph 2, line 12: tane burden with NPC disease severity [22]. However, Discussion, page 13, paragraph 3, line 19: this was likely owing to the limited viability of PBMCs Discussion, page 14, paragraph 3, line 11: uting to the 5-domain NPCCSS were locally independent Methods, page 15, paragraph 2, line 9: Incorrect formatting of citation (15) Methods, page 16, paragraph 6, line 22: Incorrect formatting of abbreviation and citation (ICC2,13) Abbreviations: MCID: Minimal clinically important difference;
  1 in total

1.  Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study.

Authors:  Eugen Mengel; Bruno Bembi; Mireia Del Toro; Federica Deodato; Matthias Gautschi; Stephanie Grunewald; Sabine Grønborg; Bénédicte Héron; Esther M Maier; Agathe Roubertie; Saikat Santra; Anna Tylki-Szymanska; Simon Day; Tara Symonds; Stacie Hudgens; Marc C Patterson; Christina Guldberg; Linda Ingemann; Nikolaj H T Petersen; Thomas Kirkegaard; Christine Í Dali
Journal:  Orphanet J Rare Dis       Date:  2020-11-23       Impact factor: 4.123

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.